Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Double-blinded, randomised, placebo-controlled, multicentre , Phase IIa study to investigate the effect efficacy, safety and tolerability of phosphorylcholine human monoclonal antibody (PC-mAb) 3G10 on arterial inflammation, together with safety and tolerability, in subjects with elevated lipoprotein a (Lp[a ])

Trial Profile

Double-blinded, randomised, placebo-controlled, multicentre , Phase IIa study to investigate the effect efficacy, safety and tolerability of phosphorylcholine human monoclonal antibody (PC-mAb) 3G10 on arterial inflammation, together with safety and tolerability, in subjects with elevated lipoprotein a (Lp[a ])

Discontinued
Phase of Trial: Phase II

Latest Information Update: 16 Jul 2018

At a glance

  • Drugs PC mAb (Primary)
  • Indications Cardiovascular disorders
  • Focus Therapeutic Use
  • Sponsors Athera Biotechnologies
  • Most Recent Events

    • 12 Jul 2018 This study has been completed in Sweden (end date: 2018-07-03).
    • 04 Jul 2018 Status changed from recruiting to discontinued.
    • 11 Oct 2017 According to an Athera Biotechnologies media release, the screening has been started in this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top